Biocon has made progress in phase-I clinical studies conducted in the US for insulin Tregopil and is looking at oral delivery of insulin. The company is set to make the next move of clinical trials with larger patient cohort. The advantage of oral insulin is rapid insulisation of the liver and a significantly lower propensity to cause postprandial hypoglycaemia then insulin Aspart. It will also minimize potential threat of hypoglycaemia and weight gain.
Company Profile : Biocon Ltd
Leave a Reply